Cargando…
Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response
Monoclonal antibody treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been widely implemented. Effects of treatment on the endogenous primary humoral response to the virus are unknown. A retrospective cohort study performed at a Veterans Health Administration me...
Autores principales: | Kim, Paul S., Dimcheff, Derek E., Siler, Andrew, Schildhouse, Richard J., Chensue, Stephen W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866167/ https://www.ncbi.nlm.nih.gov/pubmed/35218964 http://dx.doi.org/10.1016/j.clim.2022.108959 |
Ejemplares similares
-
SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients
por: Chensue, Stephen W., et al.
Publicado: (2022) -
Seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection among Veterans Affairs healthcare system employees suggests higher risk of infection when exposed to SARS-CoV-2 outside the work environment
por: Dimcheff, Derek E., et al.
Publicado: (2020) -
Functionality of Monoclonal Antibody Therapy in SARS-CoV-2
por: Ali, Ruhma, et al.
Publicado: (2022) -
Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022) -
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
por: Ragonnet-Cronin, Manon, et al.
Publicado: (2023)